Mechanic GLP-1 agents such as #semaglutide (#Ozempic #Wegovy) and #tirzepatide (#Mounjaro #Zepbound) are game-changers. In addition to obesity, they may reduce neurodegenerative diseases, such as #Parkinsons and #Alzheimers #Dementia, due to a reduction in metabolic syndrome, reduction in vascular events and neuroprotective effects.
“#GLP1 plays important role in augmenting #Iinsulin signalling inside the brain. #GLP_1 receptors…are also involved in cognition, synaptic transmission in hippocampal neurons, and cell apoptosis. Overexpression of this receptor is responsible for cognition enhancement and neuroprotection
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/
PubMed Central (PMC)Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative ReviewSemaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage form. Diabetes, insulin resistance, and obesity are responsible for the pathological ...